James P. Zidar, MD

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Part II of III - Continued TABLE 3 KEY (continued) 2) Unfractionated heparin(UFH) can be used as an alternative to enoxaparin. If UFH is used in the setting of PCI, activated clotting time (ACT) should be followed to achieve an appropriate...

Part II of III -...

08/01/2008

Journal of Invasive Cardiology

Commentary

IAGS 2002 Proceedings: Resolving Existing Restenosis (Part II of II)

08/01/2008

Luis de la Fuente ;

Hal Whitworth ;

James P. Zidar , MD;

Stefan Beyer-Enke ;

Peter Gonschior , MD;

Hall Whitworth: There is another subset of patients who will be asking for these new drug-coated stents: those with long, diffuse distal disease. We may decide to treat such patients medically, but they too will be clamoring for the new...

Hall Whitworth: There is another...

08/01/2008

Journal of Invasive Cardiology

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

A total of 5,225 patients were enrolled in the PARAGON B trial. Among these patients, the type of heparin used was known in 5,200 (99.5%). The median duration of therapy was 72.8 hours for UFH and 79.7 hours for LMWH. LMWH was used in about...

A total of 5,225 patients were...

08/01/2008

Journal of Invasive Cardiology

Commentary

IAGS Discussion ‚Äì Supporting Patients in Shock

08/01/2008

Luis de la Fuente ;

Howard A. Cohen , MD;

Gian Feltrin ;

Tom J. Linnemeier , MD;

Alfredo E. Rodriguez , MD, PhD;

James P. Zidar , MD;

Paul A. Overlie , MD, FACC, FACP;

Jeffrey Werner , MD;

Fayaz Shawl , MD;

Kirk N. Garratt , MD, MSc;

The High Mortality Among Patients in Cardiogenic Shock “LV or RV Infarcts:” What Have We Learned and Have We Made a Difference? In this symposium, we will revisit the treatment of cardiogenic shock complicating acute myocardial infarction...

The High Mortality Among...

08/01/2008

Journal of Invasive Cardiology